ICLUSIG (ponatinib) CP-CML and Ph+ ALL patient profiles
*National Comprehensive Cancer Network® (NCCN®) treatment guidelines for certain patients with T315I mutation, and it’s the only TKI with no known contraindicated BCR::ABL1 mutations.
Chronic-phase CML patient profiles
ROBERT: Experiencing resistance in chronic-phase CML with a T315I mutation
MEET ROBERT
Presenting with rising BCR::ABL1IS levels after his first TKI therapy
Robert is a 55-year-old engineer who wants to regain control of his disease to maintain his career and family life. After losing response to a 2nd-generation TKI, recent labs show the development of a T315I mutation, prompting him to consider a treatment option that addresses resistance.
Robert’s treatment journey
1. At Presentation
Loss of response to 2nd-generation TKI after originally being in remission
- PCR testing showed rising BCR::ABL1IS
- Mutation testing revealed Robert was T315I mutation positive BCR::ABL1IS
Treatment history
- First-line 2nd-generation TKI
- Originally under control and in remission
- Rising BCR::ABL1IS indicates a loss of molecular response
Laboratory results
- BCR::ABL1IS is rising and is now 6.4%, despite adherence to 2nd-generation TKI
- T315I mutation detected
2. Treatment Choice
Began second-line treatment with ICLUSIG 45 mg
- Looking to regain durable and deep disease control*
3. Early Response
Robert achieved his early response milestones
- BCR::ABL1IS down to 0.8% by MONTH 3
- Used a response-based dose-reduction approach consistent with the OPTIC* trial design (dose reduced to 15 mg after achieving ≤1% BCR::ABL1IS)1
- Slight rise in blood pressure was managed medically with no new arterial events
Conclusion
Why Robert’s physician recommends ICLUSIG
Robert and his oncologist selected ICLUSIG because it is the only TKI with no known contraindicated BCAR::ABL1 mutations and is recommended as a treatment option by the NCCN treatment guidelines for certain patients with T315I mutation.1-4
BCR::ABL1IS=BCR::ABL1 International Scale; CP-CML=chronic phase chronic myeloid leukemia; PCR=polymerase chain reaction; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI=tyrosine kinase inhibitor.
View ICLUSIG efficacy data for CP-CML
View ICLUSIG safety data for CP-CML
NAOMI: Chronic-phase CML with a suboptimal molecular response due to her intolerance with a second TKI
MEET NAOMI
BCR::ABL1 remains above target,
despite TKI cycling
Naomi is 62 years old, retired, and an active member of the community. She cycled through two 2nd-generation TKIs. Despite continuing treatment with a second-line TKI, she is experiencing interruptions in her treatment.
Naomi’s treatment journey
1. At Presentation
Naomi was treated with a first-line 2nd-generation TKI but lost response by 12 months
- Initially reached ≤1% BCR::ABL1IS
- At 12 months, her BCR::ABL1IS was 5.6%
Treatment history
- Prior failure on first-line first generation TKI
- Intolerance to second-line 2nd-generation TKI
- Interruptions in treatment
- Discontinued 2nd-generation TKI due to pleural effusions
- Disease was not under optimal control
Laboratory results
- BCR::ABL1IS was 2.1% 6 months after starting 2nd-generation TKI
2. Treatment Choice
Began treatment with second-line 2nd-generation TKI
- Experienced pleural effusions and treatment interruptions
- Discontinued at 6 months, having never reached ≤1% BCR::ABL1IS
- BCR::ABL1IS at 6 months was 2.1%
Began treatment with 3L ICLUSIG
3. Early Response
Naomi achieved her early response milestones
- BCR::ABL1IS down to 0.7% by MONTH 6
- Used a response-based dose-reduction approach consistent with the OPTIC* trial design (dose was reduced to 15 mg after achieving ≤1% BCR::ABL1IS)1
- Treatment is generally well-tolerated with no new safety events
Conclusion
Why Naomi’s physician recommends ICLUSIG
Due to her intolerance and prior loss of response to a 2nd-generation TKI, her physician recommended ICLUSIG, a 3rd-generation TKI, for the potential of a deeper response and achieving disease control.1,5*
3L=third-line; BCR::ABL1IS=BCR::ABL1 International Scale; CP-CML=chronic phase chronic myeloid leukemia; TKI=tyrosine kinase inhibitor.
View ICLUSIG efficacy data for CP-CML
View ICLUSIG safety data for CP-CML
Ph+ ALL patient profiles
JOHN: A newly diagnosed patient with Ph+ ALL, otherwise healthy
MEET JOHN
Presenting with high bone marrow blasts, but no contraindicated comorbidities
John is 48, an active father and working professional with a full calendar—school drop-offs, kids’ activities, and the hobbies that keep him feeling like himself. With so much depending on him, he wants a treatment option that has a meaningful response.
John’s treatment journey
1. At Presentation
John, an otherwise healthy adult, was diagnosed with Ph+ ALL
Laboratory results
- Bone marrow blasts 78%
- BCR::ABL1/ABL1 (p190) 78%
- Blood pressure considered in normal range, no medication
- A1c 5.5%, no medication
2. Treatment Choice
Began first-line regimen with ICLUSIG 30 mg + chemotherapy
- Targeting early molecular clearance
3. Early Response
John achieved his early response milestones
- MRD-negative CR after induction (3 months)*
- BCR::ABL1/ABL1 <0.01% by PCR after Cycle 2 (~8 weeks)
- Therapy was generally well-tolerated with abdominal pain actively monitored and managed without resulting in ICLUSIG discontinuation
Conclusion
Why John’s physician recommends ICLUSIG
After sharing decision-making with his oncologist, they chose ICLUSIG in combination with chemotherapy for the chance of a response.
A1C=glycated hemoglobin; BCR::ABL1/ABL11IS=BCR::ABL1 International Scale; CR=complete response; MRD=minimal residual disease; PCR=polymerase chain reaction; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; WBC=white blood cell.
View ICLUSIG efficacy data for Ph+ ALL
View ICLUSIG safety data for Ph+ ALL
SARAH: A newly diagnosed patient with Ph+ ALL with comorbidities
MEET SARAH
Presenting with hypertension and diabetes, both managed by medication
Sarah is 63 years old, a retired teacher in a rural community who stays active through local events and social groups. Despite managing type 2 diabetes and hypertension, she remains generally fit and engaged, and is proud of maintaining her independence and role in the community. With her new Ph+ ALL diagnosis, she worries about how treatment may affect her ability to stay involved and live the life she values.
Sarah’s treatment journey
1. At Presentation
Sarah was managing type 2 diabetes and hypertension when she was newly diagnosed with Ph+ ALL
Comorbidities
- Type 2 diabetes (controlled, metformin)
- Hypertension (controlled, ACE inhibitor)
Laboratory results
- Bone marrow blasts 62%
- BCR::ABL1/ABL1 (p190) 64%
- WBC 21x10
2. Treatment Choice
Began first-line regimen with ICLUSIG + chemotherapy
- Targeting MRD-negative CR by the end of the induction period (~3 months)6
3. Early Response
Sarah achieved her early response milestones
- MRD negative by CR at end of induction (3 months)
- Increased blood pressure was managed with medication dose adjustment and did not result in discontinuation of ICLUSIG
Conclusion
Why Sarah’s physician recommends ICLUSIG
Sarah’s physician recommended ICLUSIG + chemotherapy after careful discussion with Sarah about managing treatment with her comorbidities.1,6